Cargando…
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
PURPOSE: The Recurrence Score test is validated to predict benefit of adjuvant chemotherapy. TransNEOS, a translational study of New Primary Endocrine-therapy Origination Study (NEOS), evaluated whether Recurrence Score results can predict clinical response to neoadjuvant letrozole. METHODS: NEOS is...
Autores principales: | Iwata, Hiroji, Masuda, Norikazu, Yamamoto, Yutaka, Fujisawa, Tomomi, Toyama, Tatsuya, Kashiwaba, Masahiro, Ohtani, Shoichiro, Taira, Naruto, Sakai, Takehiko, Hasegawa, Yoshie, Nakamura, Rikiya, Akabane, Hiromitsu, Shibahara, Yukiko, Sasano, Hironobu, Yamaguchi, Takuhiro, Sakamaki, Kentaro, Bailey, Helen, Cherbavaz, Diana B., Jakubowski, Debbie M., Sugiyama, Naoko, Chao, Calvin, Ohashi, Yasuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394785/ https://www.ncbi.nlm.nih.gov/pubmed/30242578 http://dx.doi.org/10.1007/s10549-018-4964-y |
Ejemplares similares
-
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023) -
Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022) -
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021) -
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study
por: Yamamoto, Yutaka, et al.
Publicado: (2020) -
Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)